Vimarsana
Biggest News Aggregation in the World

Page 2 - Oaktree Acquisition News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oaktree Acquisition. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oaktree Acquisition Today - Breaking & Trending Today

Alvotech Appoints Interim Chief Quality Officer - Vimarsana News

Alvotech Appoints Interim Chief Quality Officer

REYKJAVIK, Iceland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Christina Siniscalchi will join its corporate leadership team as interim Chief Quality Officer. Christina succeeds Sandra Casaca, who is leaving the company as a part of other organizational changes. Christina Siniscalchi has for over ten years served in senior quality positions

Source: yahoo.com
Alvotech and Teva Announce U.S. Approval of SIMLANDI® - Vimarsana News

Alvotech and Teva Announce U.S. Approval of SIMLANDI®

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar...

Alvotech and Teva Announce U.S. Approval of SIMLANDI® - Vimarsana News

Alvotech and Teva Announce U.S. Approval of SIMLANDI®

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S.  SIMLANDI is the first biosimilar...

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® - Vimarsana News

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership...

Alvotech and Teva Announce U.S. Approval of SIMLANDI (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira - Vimarsana News

Alvotech and Teva Announce U.S. Approval of SIMLANDI (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira

24.02.2024 - Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as ...